The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Gynecologic Oncology

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2009.10.073PMID 19945740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors for high‐risk early‐stage epithelial ovarian cancer

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

  2008cited by this paper
• Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

  2007cited by this paper
• Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

  2006cited by this paper
• Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

  2006cited by this paper
• Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.

  2006cited by this paper
• External validity of randomised controlled trials: "to whom do the results of this trial apply?".

  2005cited by this paper
• Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

  2005cited by this paper
• Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon

  2005cited by this paper
• Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.

  2005cited by this paper
• Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

  2005cited by this paper
• Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

  2003cited by this paper
• Carcinoma of the ovary

  2003cited by this paper
• Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.

  2003cited by this paper
• Carcinoma of the Ovary

  2003cited by this paper
• International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

  2003cited by this paper
• Clinical characteristics of clear cell carcinoma of the ovary

  2000cited by this paper
• Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

  2000cited by this paper
• Can randomised trials inform clinical decisions about individual patients?

  1999cited by this paper
• A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study.

  1997cited by this paper
• Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).

  1996cited by this paper
• Natural history and prognosis of untreated stage I epithelial ovarian carcinoma.

  1996cited by this paper
• The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society.

  1995cited by this paper
• The national cancer data base report on ovarian cancer

  1995cited by this paper
• Alteration of the p53 Tumor Suppressor Gene Occurs Independently of K‐ras Activation and More Frequently in Serous Adenocarcinomas than in Other Common Epithelial Tumors of the Human Ovary

  1994cited by this paper
• FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.

  1994cited by this paper
• Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.

  1994cited by this paper
• A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

  1993cited by this paper
• National survey of ovarian carcinoma VI: Critical assessment of Current International Federation of Gynecology and Obstetrics Staging System

  1993cited by this paper
• Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma

  1993cited by this paper
• Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.

  1993cited by this paper
• ‘Moderate-risk’ ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation

  1993cited by this paper
• Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five‐year cancer registry review

  1992cited by this paper
• Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

  1992cited by this paper
• Prognostic factors and adjuvant treatment in early epithelial ovarian cancer

  1992cited by this paper
• K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.

  1991cited by this paper
• Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

  1990cited by this paper
• Prognostic factors for survival in Stage I epithelial ovarian carcinoma

  1990cited by this paper
• Prognostic Factors in Patients With Stage I Epithelial Ovarian Cancer

  1990cited by this paper

• Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study.

  2026cites this paper
• De-escalation in stage IC epithelial ovarian cancer: adjuvant treatment.

  2026cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2025 update

  2025influential citation
• Surgery in Ovarian Cancer—Brazilian Society of Surgical Oncology Consensus

  2025cites this paper
• Management of early-stage ovarian cancer: open questions and debated issues.

  2025cites this paper
• Ovarian clear cell carcinoma: open questions on the management and treatment algorithm

  2025cites this paper
• The Oncology Team of The Karlovac General Hospital Was the First in Croatia To Perform Ovarian Cancer Surgery Using the Latest ICG Technology-Case Report

  2025cites this paper
• Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.

  2025cites this paper
• SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023)

  2024cites this paper
• From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer

  2024influential citation
• British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024.

  2024cites this paper
• Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

  2023cites this paper
• The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre

  2023influential citation
• Systemische Therapie der epithelialen serösen Ovarialkarzinome

  2023cites this paper
• The Role of Interleukin 6 (IL6), Cancer Antigen—125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients

  2023cites this paper
• Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options

  2023cites this paper
• Clinical and translational advances in ovarian cancer therapy

  2023cites this paper
• Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2023cites this paper
• Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study

  2023cites this paper
• Immune‐Hot tumor features associated with recurrence in early‐stage ovarian clear cell carcinoma

  2023cites this paper
• Is There a Survival Benefit of Adjuvant Chemotherapy in Stage IC1 Epithelial Ovarian Cancer Patients? A Meta-Analysis

  2022cites this paper
• Adjuvant chemotherapy is not associated with improved overall survival with stage I endometrioid ovarian cancer patients in a SEER cohort

  2022cites this paper
• The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.

  2022cites this paper
• Early-Stage epithelial ovarian cancer: Predictors of survival

  2022cites this paper
• Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study

  2022cites this paper
• Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.

  2022cites this paper
• Symptoms of Women With High-Risk Early-Stage Ovarian Cancer

  2022cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Ovarian Cancer, Version 2.2020

  2021cites this paper
• An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology

  2021cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

  2021cites this paper
• Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.

  2021cites this paper
• Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment

  2021cites this paper
• Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.

  2021cites this paper
• Medikamentöse Therapie des Ovarialkarzinoms

  2021influential citation
• Early-stage epithelial ovarian cancer: is systematic lymph node staging mandatory?

  2021cites this paper
• Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma

  2021cites this paper
• Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Clinical guidelines for diagnosis, treatment and monitoring of patients with ovarian cancer, Fallopian tube cancer and primary peritoneal can

  2021cites this paper
• Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.

  2021cites this paper
• Recommendations on the pharmacological treatment of epithelial ovarian cancer in Mexico.

  2021cites this paper
• Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?

  2021influential citation
• Ovarian Cancer, Early Primary Disease

  2021cites this paper
• Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM)

  2020cites this paper
• Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?

  2020cites this paper
• Hormonal Pathology of the Uterus

  2020cites this paper
• Endometriosis and Endometriosis-Associated Ovarian Cancer (EAOC).

  2020cites this paper
• Treatment of epithelial ovarian cancer

  2020cites this paper
• Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy.

  2020cites this paper
• Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer.

  2020cites this paper
• An exploratory analysis about cycles of adjuvant chemotherapy and outcomes by substage for stage I ovarian clear cell carcinoma: a single institution retrospective study.

  2020cites this paper
• Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles

  2020cites this paper
• The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.

  2019cites this paper
• Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation

  2019cites this paper
• Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes

  2019cites this paper
• Predictive factors of recurrence in patients with early‐stage epithelial ovarian cancer

  2019cites this paper
• [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

  2019cites this paper
• Epithelial ovarian cancer.

  2019cites this paper
• Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.

  2019cites this paper
• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  2019cites this paper
• ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease

  2019cites this paper
• Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.

  2019cites this paper
• Feasibility of Performing Laparoscopic Completion Staging in Incidentally Diagnosed Early-Stage Ovarian Carcinoma Patients

  2019cites this paper
• Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.

  2019cites this paper
• Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.

  2019cites this paper
• ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

  2019cites this paper
• Ovarian Cancer

  2019cites this paper
• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cites this paper
• Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.

  2018cites this paper
• Clear cell carcinoma of the ovary

  2018cites this paper
• Surgery in ovarian cancer – Brazilian Society of Surgical Oncology consensus

  2018cites this paper
• Tilburg University Course of chemotherapy induced peripheral neuropathy and its impact on health related quality of life among ovarian cancer patients Bonhof,

  2018cites this paper
• 11 – Epithelial Ovarian Cancer

  2018cites this paper
• Management of newly diagnosed or recurrent ovarian cancer.

  2018cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum

  2018cites this paper
• Diagnosis and Treatment of Ovarian Cancer.

  2018cites this paper
• Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

  2017cites this paper
• Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013

  2017cites this paper
• Updates on Rare Epithelial Ovarian Carcinoma

  2017cites this paper
• Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer.

  2017cites this paper
• Cancer de l’ovaire : prise en charge pluridisciplinaire du cancer de l’ovaire en première ligne: Recommandations Saint-Paul-de-Vence 2016

  2017cites this paper
• Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.

  2017cites this paper
• Importancia de la temperatura de la quimioterapia intraperitoneal intraoperatoria con paclitaxel en el tratamiento quirúrgico radical de la carcinomatosis peritoneal de origen ovárico. Hipertermia versus normotermia

  2017cites this paper
• Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy.

  2017cites this paper
• Contemporary Treatment Strategies for Rare Epithelial Ovarian Cancers

  2017cites this paper
• Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.

  2017cites this paper
• Malignant Brenner tumor of the ovary: Review and case report

  2017cites this paper
• Role of radiation therapy.

  2017cites this paper
• Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.

  2017cites this paper
• First-Line Systemic Therapy (Chemo/Antiangiogenics)

  2017cites this paper
• Comparison of Laparoscopy and Laparotomy in Surgical Staging of Apparent Early Ovarian Cancer

  2016cites this paper
• The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma

  2016cites this paper
• Optimal primary therapy of ovarian cancer.

  2016cites this paper
• First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies.

  2016cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum

  2015cites this paper
• Systematic review of laparoscopic comprehensive staging surgery in early stage ovarian cancer: a meta-analysis.

  2015cites this paper
• Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.

  2015cites this paper
• Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.

  2015cites this paper
• Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.

  2015cites this paper
• Treatment of Early Ovarian Cancer

  2015cites this paper
• A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

  2015cites this paper